An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: A general practice study

International Journal of Clinical Practice

Volumn 53, Issue 6, 1999, Pages 422-426

  Neil, H A W ^a   Fowler, G ^d   Patel, H ^b,c   Eminton, Z ^b   Maton, S ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Parke Davis Medical Division   (United Kingdom)

^c Parke Davis Medical Division   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; GENERAL PRACTICE; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION; TITRIMETRY;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; FAMILY PRACTICE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRROLES; TREATMENT OUTCOME;

EID: 0032829583     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events): principal results. Heart 1996; 75: 334-342.
2. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease. Principal results. Eur Heart J 1997; 18: 1569-1582.
3. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81(5): 582-587.
4. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15(5): 678-682.
5. Betteridge DJ, Dodson PM, Durrington PN et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359-369.
6. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl 2): S1-S29.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
8. Shepherd J, Cobbe SM, Ford I et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
9. Sacks FM, Pfeffer MA, Moyé LA et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
10. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-1357.
11. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-1622.
12. Pedersen TR. Aggressive lipid-lowering therapy: a clinical imperative. Eur Heart J 1998; 19(suppl M): M15-M21.
13. Dart A, Jerums G, Nicholson G et al. A multicenter, double-blind, 1-year study comparing safety and efficacy of atorvastatin and simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44.
14. Davidson MM, McKenney JM, Stein EA et al. I. Comparison of one-year efficacy and safety of atorvastatin compared to lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475-1481.
15. Bertolini S, Bitollo Bon G, Campbell LM et al. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-197.
16. Koren MJ, Smith DG, Hunninghake DB et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 1998; 14(1): 59-70.
17. Smith DG, Leslie SJ, Szucs TD et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target: comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Drug Invest 1999; 17(3): 185-193.
18. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.
19. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor) a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158: 577-584.